NASDAQ:BVXV - BIONDVAX PHARMA/S Stock Price, Forecast & News

BIONDVAX PHARMA/S trades on the NASDAQ under the ticker symbol "BVXV."

BIONDVAX PHARMA/S (NASDAQ:BVXV) released its earnings results on Tuesday, November, 26th. The company reported ($0.57) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.03) by $0.54. View BIONDVAX PHARMA/S's Earnings History.

BIONDVAX PHARMA/S is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for BIONDVAX PHARMA/S.

News headlines about BVXV stock have trended positive recently, according to InfoTrie Sentiment. The research group scores the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. BIONDVAX PHARMA/S earned a media sentiment score of 3.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for BIONDVAX PHARMA/S.

BIONDVAX PHARMA/S saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 49,500 shares, an increase of 66.7% from the January 15th total of 29,700 shares. Based on an average daily volume of 31,000 shares, the days-to-cover ratio is currently 1.6 days. Currently, 0.8% of the shares of the company are short sold. View BIONDVAX PHARMA/S's Current Options Chain.

Some companies that are related to BIONDVAX PHARMA/S include La Jolla Pharmaceutical (LJPC), Verona Pharma (TARA), CASI Pharmaceuticals (CASI), ADMA Biologics (ADMA), LogicBio Therapeutics (LOGC), Jounce Therapeutics (JNCE), Windtree Therapeutics (WINT), Fennec Pharmaceuticals (FENC), Dyadic International (DYAI), Solid Biosciences (SLDB), X4 Pharmaceuticals (XFOR), Erytech Pharma (ERYP), Brainstorm Cell Therapeutics (BCLI), Gamida Cell (GMDA) and Axcella Health (AXLA).

Based on aggregate information from My MarketBeat watchlists, some companies that other BIONDVAX PHARMA/S investors own include Gilead Sciences (GILD), AbbVie (ABBV), Pluristem Therapeutics (PSTI), Exelixis (EXEL), BIOLINERX LTD/S (BLRX), Agilent Technologies (A), Enterprise Products Partners (EPD), AT&T (T), NovaBay Pharmaceuticals (NBY) and Akari Therapeutics (AKTX).

(BVXV) raised $10 million in an IPO on Tuesday, May 12th 2015. The company issued 1,400,000 shares at $7.32 per share. Aegis Capital Corp acted as the underwriter for the IPO.

BIONDVAX PHARMA/S's stock is owned by many different of institutional and retail investors. Top institutional investors include Mariner LLC (0.87%) and Renaissance Technologies LLC (0.22%).

BVXV stock was acquired by a variety of institutional investors in the last quarter, including Mariner LLC and Renaissance Technologies LLC.

Shares of BVXV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of BVXV stock can currently be purchased for approximately $9.15.

BIONDVAX PHARMA/S has a market capitalization of $59.80 million. The company earns $-23,410,000.00 in net income (profit) each year or ($3.60) on an earnings per share basis. BIONDVAX PHARMA/S employs 14 workers across the globe.View Additional Information About BIONDVAX PHARMA/S.

The official website for BIONDVAX PHARMA/S is http://www.biondvax.com/.

BIONDVAX PHARMA/S's mailing address is Jerusalem BioPark 2nd floor Hadassah Ein Kerem Campus, Jerusalem L3, 74036. The company can be reached via phone at 972-8930-2529 or via email at [email protected]